Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 39
Inquire Before Buying

Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017, provides an overview of the Hepatic - Colorectal Metastasis (Oncology) pipeline landscape.

Patients who present with hepatic colorectal metastases are usually asymptomatic. Symptoms such as abdominal pain and weight loss are associated with advanced (high-volume) metastases and a poor prognosis. Although liver resection is not the primary treatment for most patients with hepatic colorectal metastases, appropriate liver resection is the standard of care for treatment of patients with isolated hepatic colorectal metastases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatic - Colorectal Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic - Colorectal Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatic - Colorectal Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 4 respectively.

Hepatic - Colorectal Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic - Colorectal Metastasis (Oncology).

- The pipeline guide reviews pipeline therapeutics for Hepatic - Colorectal Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hepatic - Colorectal Metastasis (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hepatic - Colorectal Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic - Colorectal Metastasis (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hepatic - Colorectal Metastasis (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hepatic - Colorectal Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatic - Colorectal Metastasis - Overview
Hepatic - Colorectal Metastasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hepatic - Colorectal Metastasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatic - Colorectal Metastasis - Companies Involved in Therapeutics Development
Alfact Innovation
Cellular Biomedicine Group Inc
Delcath Systems Inc
Gradalis Inc
Hepatic - Colorectal Metastasis - Drug Profiles
ALF-5755 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBM-EGFR.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
contusugene ladenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gemogenovatucel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSVRbp-450 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melphalan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatic - Colorectal Metastasis - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hepatic - Colorectal Metastasis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hepatic - Colorectal Metastasis - Pipeline by Alfact Innovation, H2 2017
Hepatic - Colorectal Metastasis - Pipeline by Cellular Biomedicine Group Inc, H2 2017
Hepatic - Colorectal Metastasis - Pipeline by Delcath Systems Inc, H2 2017
Hepatic - Colorectal Metastasis - Pipeline by Gradalis Inc, H2 2017
Hepatic - Colorectal Metastasis - Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Hepatic - Colorectal Metastasis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • United States Head and Neck Cancer Treatment Market Report 2017
    Published: 19-Jan-2018        Price: US 3800 Onwards        Pages: 105
    In this report, the United States Head and Neck Cancer Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and ......
  • Global Chronic Lymphocytic Leukemia Therapeutics Market Size, Status and Forecast 2025
    Published: 09-Jan-2018        Price: US 3300 Onwards        Pages: 91
    This report studies the global Chronic Lymphocytic Leukemia Therapeutics market, analyzes and researches the Chronic Lymphocytic Leukemia Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - Amgen - Abbott - Roche AG - Novartis - Johnson and Johnson - Sanofi Genzyme Corporation - Akebia Therapeutics - Celgene......
  • Global Lung Cancer Therapeutics Market Size, Status and Forecast 2025
    Published: 09-Jan-2018        Price: US 3300 Onwards        Pages: 98
    This report studies the global Lung Cancer Therapeutics market, analyzes and researches the Lung Cancer Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - Roche - Merck - AstraZeneca - Sanofi-Aventis - Eli Lilly and Company - Abbott - Akebia Therapeutics - Agennix AG Market segment by Regions......
  • Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report
    Published: 05-Jan-2018        Price: US 3500 Onwards        Pages: 73
    Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market ......
  • Medulloblastoma - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 197
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H2 2017, provides an overview of the Medulloblastoma (Oncology) pipeline landscape. Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the mo......
  • High-Grade Glioma - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 333
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H2 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape. Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of co......
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 766
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2017, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape. Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radi......
  • Colorectal Cancer - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2500 Onwards        Pages: 1962
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape. Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation,......
  • Pancreatic Cancer - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2500 Onwards        Pages: 2270
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs